|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Pfister DG, Benson AB III and Somerfield
MR: Clinical practice. Surveillance strategies after curative
treatment of colorectal cancer. N Engl J Med. 350:2375–2382. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mandel JS, Church TR, Bond JH, et al: The
effect of fecal occult-blood screening on the incidence of
colorectal cancer. N Engl J Med. 343:1603–1607. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winawer S, Fletcher R, Rex D, et al:
Colorectal cancer screening and surveillance: clinical guidelines
and rationale-update based on new evidence. Gastroenterology.
124:544–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith A, Young GP, Cole SR and Bampton P:
Comparison of a brush-sampling fecal immunochemical test for
hemoglobin with a sensitive guaiac-based fecal occult blood test in
detection of colorectal neoplasia. Cancer. 107:2152–2159. 2006.
View Article : Google Scholar
|
|
6
|
Levi Z, Rozen P, Hazazi R, et al: A
quantitative immunochemical fecal occult blood test for colorectal
neoplasia. Ann Intern Med. 146:244–255. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kronborg O, Fenger C, Olsen J, Jørgensen
OD and Søndergaard O: Randomised study of screening for colorectal
cancer with faecal-occult-blood test. Lancet. 348:1467–1471. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hardcastle JD, Chamberlain JO, Robinson
MH, et al: Randomised controlled trial of faecal-occult-blood
screening for colorectal cancer. Lancet. 348:1472–1477. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lieberman DA and Weiss DG: One-time
screening for colorectal cancer with combined fecal occult-blood
testing and examination of the distal colon. N Engl J Med.
345:555–560. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sung JJ, Chan FK, Leung WK, et al:
Screening for colorectal cancer in Chinese: comparison of fecal
occult blood test, flexible sigmoidoscopy, and colonoscopy.
Gastroenterology. 124:608–614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Imperiale TF, Ransohoff DF, Itzkowitz SH,
Turnbull BA and Ross ME: Fecal DNA versus fecal occult blood for
colorectal-cancer screening in an average-risk population. N Engl J
Med. 351:2704–2714. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morikawa T, Kato J, Yamaji Y, Wada R,
Mitsushima T and Shiratori Y: A comparison of the immunochemical
fecal occult blood test and total colonoscopy in the asymptomatic
population. Gastroenterology. 129:422–428. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahlquist DA, Skoletsky JE, Boynton KA, et
al: Colorectal cancer screening by detection of altered human DNA
in stool: feasibility of a multitarget assay panel.
Gastroenterology. 119:1219–1227. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong SM, Traverso G, Johnson C, et al:
Detecting colorectal cancer in stool with the use of multiple
genetic targets. J Natl Cancer Inst. 93:858–865. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Traverso G, Shuber A, Levin B, et al:
Detection of APC mutations in fecal DNA from patients with
colorectal tumors. N Engl J Med. 346:311–320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Diehl F, Schmidt K, Durkee KH, et al:
Analysis of mutations in DNA isolated from plasma and stool of
colorectal cancer patients. Gastroenterology. 135:489–498. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lenhard K, Bommer GT, Asutay S, et al:
Analysis of promoter methylation in stool: a novel method for the
detection of colorectal cancer. Clin Gastroenterol Hepatol.
3:142–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen WD, Han ZJ, Skoletsky J, et al:
Detection in fecal DNA of colon cancer-specific methylation of the
nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou H, Harrington J, Rego RL and Ahlquist
DA: A novel method to capture methylated human DNA from stool:
implications for colorectal cancer screening. Clin Chem.
53:1646–1651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Müller HM, Oberwalder M, Fiegl H, et al:
Methylation changes in faecal DNA: a marker for colorectal cancer
screening? Lancet. 363:1283–1285. 2004.PubMed/NCBI
|
|
21
|
Itzkowitz SH, Jandorf L, Brand R, et al:
Improved fecal DNA test for colorectal cancer screening. Clin
Gastroenterol Hepatol. 5:111–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leung WK, To KF, Man EP, et al: Detection
of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal
samples of patients with colorectal cancer or polyps. Am J
Gastroenterol. 102:1070–1076. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boynton KA, Summerhayes IC, Ahlquist DA
and Shuber AP: DNA integrity as a potential marker for stool-based
detection of colorectal cancer. Clin Chem. 49:1058–1065. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou H, Harrington JJ, Klatt KK and
Ahlquist DA: A sensitive method to quantify human long DNA in
stool: relevance to colorectal cancer screening. Cancer Epidemiol
Biomarkers Prev. 15:1115–1119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamao T, Matsumura Y, Shimada Y, et al:
Abnormal expression of CD44 variants in the exfoliated cells in the
feces of patients with colorectal cancer. Gastroenterology.
114:1196–1205. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanaoka S, Yoshida K, Miura N, Sugimura H
and Kajimura M: Potential usefulness of detecting cyclooxygenase 2
messenger RNA in feces for colorectal cancer screening.
Gastroenterology. 127:422–427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lagerholm S, Lagerholm S, Dutta S and Nair
P: Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in
colorectal cancer. Scand J Gastroenterol. 40:1343–1350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yajima S, Ishii M, Matsushita H, et al:
Expression profiling of fecal colonocytes for RNA-based screening
of colorectal cancer. Int J Oncol. 31:1029–1037. 2007.PubMed/NCBI
|
|
29
|
Koga Y, Yasunaga M, Moriya Y, et al:
Detection of colorectal cancer cells from feces using quantitative
real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci.
99:1977–1983. 2008.PubMed/NCBI
|
|
30
|
Takai T, Kanaoka S, Yoshida K, et al:
Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assay
as a marker for colorectal cancer screening. Cancer Epidemiol
Biomarkers Prev. 18:1888–1893. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu YJ, Majumdar AP, Nechvatal JM, et al:
Exfoliated cells in stool: a source for reverse
transcription-PCR-based analysis of biomarkers of gastrointestinal
cancer. Cancer Epidemiol Biomarkers Prev. 17:455–458.
2008.PubMed/NCBI
|
|
32
|
Kitahara O, Furukawa Y, Tanaka T, et al:
Alterations of gene expression during colorectal carcinogenesis
revealed by cDNA microarrays after laser-capture microdissection of
tumor tissues and normal epithelia. Cancer Res. 61:3544–3549.
2001.
|
|
33
|
Andreu P, Colnot S, Godard C, et al:
Identification of the IFITM family as a new molecular marker in
human colorectal tumors. Cancer Res. 66:1949–1955. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Akobeng AK: Understanding diagnostic tests
3: receiver operating characteristic curves. Acta Pediatrica.
96:644–647. 2007. View Article : Google Scholar : PubMed/NCBI
|
